![](/wp-content/uploads/2021/03/abstractheadergraphic2009.gif)
Meeting Abstract
P1.129 Sunday, Jan. 4 Effects of Chelating Agents on Manganese Accumulations in Gill of the Eastern Oyster, Crassostrea virginica MURRAY, S.*; PERDOMO, Y.; CARROLL, M.A.; CATAPANE, E.J.; Kingsborough Community College; Medgar Evers College; Medgar Evers College; Medgar Evers College invivo@mec.cuny.edu
Manganese (Mn)is needed in small amounts for normal physiological functions, but high amounts are toxic and causes Manganism. Manganism has been misdiagnosed as Parkinsons disease. The two are similar and due to disruptions in dopamine neurons in the brain. Recently, p-aminosalicylic acid (PAS) has been used to alleviate symptoms of Manganism. PAS has anti-inflammatory and chelating properties. The ability of PAS to ameliorate symptoms of Manganism is postulated to be related to its chelating actions. Crassostrea virginica, possesses a dopaminergic system innervating its gill. Our lab showed manganese disrupts this dopaminergic innervation. We also found PAS caused a dose dependant decrease in Mn accumulations in oyster gill. This study sought to determine if other chelating agents caused similar reductions in Mn accumulations as PAS. We incubated gills of C. virginica, for 10 hour with 500 µM of Mn, followed by 3 day treatments with up to 2 mM of the metal chelators, diaminocyclohexanetetraacetic acid (DACH), sodium EDTA (EDTAna) or calcium EDTA (EDTAca). Mn levels were measured using a Perkin Elmer AA800 Atomic Absorption spectrophotometer with a THGA graphite furnace. All 3 chelating agents reduced Mn accumulations compared to controls. DACH was the most effective, followed by EDTAca and EDTAna. The study shows the chelating agents are effective in reducing Mn accumulations and supports the hypothesis that the mechanism of action of PAS in treatment of Manganism is related to its chelating abilities. This work was supported in part by the Louis Stoke Alliance for Minority Participation (LSAMP) in Science, and by grants 2R25GM06003-05 of the Bridge Program of NIGMS, 0516041071 of NYSDOE, 0622197 of the DUE Program of NSF, and 0420359 of the MRI Program of NSF.